Xencor/$XNCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xencor
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Ticker
$XNCR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
250
ISIN
US98401F1057
Website
Xencor Metrics
BasicAdvanced
$646M
-
-$3.05
0.86
-
Price and volume
Market cap
$646M
Beta
0.86
52-week high
$26.42
52-week low
$7.16
Average daily volume
715K
Financial strength
Current ratio
5.894
Quick ratio
5.737
Long term debt to equity
25.946
Total debt to equity
34.726
Interest coverage (TTM)
-4.62%
Profitability
EBITDA (TTM)
-152.834
Gross margin (TTM)
-80.30%
Net profit margin (TTM)
-163.17%
Operating margin (TTM)
-129.37%
Effective tax rate (TTM)
-0.95%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-11.42%
Return on equity (TTM)
-34.05%
Valuation
Price to revenue (TTM)
4.859
Price to book
1.01
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-3.606
Free cash flow yield (TTM)
-27.73%
Free cash flow per share (TTM)
-251.55%
Growth
Revenue change (TTM)
-25.88%
Earnings per share change (TTM)
27.24%
3-year revenue growth (CAGR)
-26.97%
10-year revenue growth (CAGR)
30.58%
3-year earnings per share growth (CAGR)
19.66%
10-year earnings per share growth (CAGR)
17.75%
What the Analysts think about Xencor
Analyst ratings (Buy, Hold, Sell) for Xencor stock.
Bulls say / Bears say
Xencor's strategic focus on advancing high-potential XmAb CD3 and CD28 T-cell engagers, along with the evaluation of vudalimab in metastatic castration-resistant prostate cancer and front-line non-small cell lung cancer, positions the company to address significant unmet medical needs. (Xencor Q4 2023 Financial Results)
The partial monetization of royalties from Ultomiris and Monjuvi has bolstered Xencor's financial position, providing over $325 million in proceeds, which can be reinvested into research and development initiatives. (Xencor Q4 2023 Financial Results)
Xencor's collaborations with major pharmaceutical companies, such as Janssen Biotech, have led to milestone payments and the advancement of bispecific antibody programs into Phase 1 clinical development, indicating strong partnership dynamics and potential future revenue streams. (Xencor Q4 2023 Financial Results)
Despite increased revenues, Xencor reported a net loss of $126.1 million for the full year 2023, primarily due to heightened research and development expenses, raising concerns about the company's path to profitability. (Xencor Q4 2023 Financial Results)
The company's reliance on milestone payments and royalties from collaborations introduces variability in revenue streams, which may impact financial stability if partnerships do not yield expected outcomes. (Xencor Q4 2023 Financial Results)
Xencor's recent workforce reduction of approximately 10% to align resources with its clinical development focus may indicate internal challenges and could affect morale and productivity. (Xencor Q4 2023 Financial Results)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Xencor Financial Performance
Revenues and expenses
Xencor Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xencor stock?
Xencor (XNCR) has a market cap of $646M as of July 18, 2025.
What is the P/E ratio for Xencor stock?
The price to earnings (P/E) ratio for Xencor (XNCR) stock is 0 as of July 18, 2025.
Does Xencor stock pay dividends?
No, Xencor (XNCR) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Xencor dividend payment date?
Xencor (XNCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Xencor?
Xencor (XNCR) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.